Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Nov 1;202(9):1202-1204.
doi: 10.1164/rccm.202006-2600ED.

Inhaled Corticosteroid Withdrawal in Chronic Obstructive Pulmonary Disease: Can IMPACT Help?

Samy Suissa  1   2   3
Affiliations
Editorial

Inhaled Corticosteroid Withdrawal in Chronic Obstructive Pulmonary Disease: Can IMPACT Help?

Samy Suissa. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Rate ratio and 95% confidence interval of moderate or severe chronic obstructive pulmonary disease exacerbations comparing inhaled corticosteroid (ICS) withdrawal with ICS continuation from the WISDOM (Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management), INSTEAD (Indacaterol: Switching Non-exacerbating Patients with Moderate COPD from Salmeterol/Fluticasone to Indacaterol), and IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trials, with the latter computed among all 7,360 users of ICSs and among the 2,406 users of triple therapy at baseline (6, 7, 11).
See this image and copyright information in PMC

Comment on

References

    1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Am J Respir Crit Care Med. 2017;195:557–582. - PubMed
    1. Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease (2019 Report) Fontana, WI: Global Initiative for Chronic Obstructive Lung Disease; 2019 [accessed 2020 Sep 23]. Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14N... - PubMed
    1. Ghosh S, Anderson WH, Putcha N, Han MK, Curtis JL, Criner GJ, et al. Current and former investigators of the SPIROMICS sites and reading centers; Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS. Alignment of inhaled chronic obstructive pulmonary disease therapies with published strategies. Ann Am Thorac Soc. 2019;16:200–208. - PMC - PubMed
    1. Koblizek V, Milenkovic B, Barczyk A, Tkacova R, Somfay A, Zykov K, et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE study. Eur Respir J. 2017;49:1601446. - PMC - PubMed
    1. Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45:525–537. - PubMed

MeSH terms

Substances